Startups support and rare disease drug plans for India, ET HealthWorld


New Delhi: As the newly elected government completed its first 100 days in power, the Department of Health Research (DHR) has presented its 100 days report card listing out its key achievements and future plans for promoting healthcare research and development in the country.

Among its key achievements the department has enlisted creation of Med-Tech Mitra, a platform to help start-ups and private players by assisting in securing ‘clinical validation’ and ‘upscaling’ services; Implementation of National One Health Mission for Pandemic Preparedness; upgrading ‘six Viral Research and Diagnostic Laboratories (VRDLs) into Integrated Research and Diagnostic Laboratories (IRDLs) to cover larger domain of infectious diseases.’

With respect to its future initiatives DHR mentioned, “Inauguration of Centre for Evidence-Based Guidelines to nationwide standardisation medical practices; a program developing 12 indigenous drugs for 8 rare diseases; the First in the World challenge to fund 50 high-risk, high-reward innovations in biomedical research among others.

In the official release the ministry has stated, “The above initiatives are slated for launch in October 2024 by the Union Health Minister.”

“These initiatives represent transformative steps in healthcare innovation, pandemic preparedness, and the development of indigenous medical solutions, contributing to a healthier, more resilient and Atmanirbhar Bharat,” Health Minister, JP Nadda said while announcing the implementation of 100 day programmes of DHR which functions under the Ministry of Health and Family Welfare (MoHFW).

  • Published On Sep 23, 2024 at 04:52 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App




Source link

Latest articles

Related articles

Discover more from Technology Tangle

Subscribe now to keep reading and get access to the full archive.

Continue reading

0